According to a report by BioSpace, a Marketing Authorisation Application (MAA) seeking approval of pegloticase (Krystexxa®) for the treatment of chronic gout in adults refractory to conventional therapy has been accepted for review by the European Medicines Agency (EMA).  Pegloticase is already approved by the US FDA for use within this indication (see link below for related news item).